Current status of ctDNA in precision oncology for hepatocellular carcinoma.

Citation metadata

Date: Apr. 26, 2021
Publisher: BioMed Central Ltd.
Document Type: Article
Length: 10,362 words
Lexile Measure: 1590L

Document controls

Main content

Abstract :

The conventional method used to obtain a tumor biopsy for hepatocellular carcinoma (HCC) is invasive and does not evaluate dynamic cancer progression or assess tumor heterogeneity. It is thus imperative to create a novel non-invasive diagnostic technique for improvement in cancer screening, diagnosis, treatment selection, response assessment, and predicting prognosis for HCC. Circulating tumor DNA (ctDNA) is a non-invasive liquid biopsy method that reveals cancer-specific genetic and epigenetic aberrations. Owing to the development of technology in next-generation sequencing and PCR-based assays, the detection and quantification of ctDNA have greatly improved. In this publication, we provide an overview of current technologies used to detect ctDNA, the ctDNA markers utilized, and recent advances regarding the multiple clinical applications in the field of precision medicine for HCC. Keywords: ctDNA, Hepatocellular carcinoma, Mutation, Methylation

Source Citation

Source Citation   

Gale Document Number: GALE|A661418764